KURA ONCOLOGY INC. -
6.0900
16-May-25 14:32:25
15 minutes delayed
Stocks
+0.1400
+2.35%
Today's range
5.8900 - 6.2000
ISIN
N/A
Source
NASDAQ
-
05 Nov 2024 09:09:54 By Nasdaq GlobeNewswire
-
Kura Oncology to Report Third Quarter 2024 Financial Results
31 Oct 2024 07:30:00 By Nasdaq GlobeNewswire
-
24 Oct 2024 07:30:00 By Nasdaq GlobeNewswire
-
23 Oct 2024 07:30:00 By Nasdaq GlobeNewswire
-
Kura Oncology Announces Publication of Ziftomenib Phase 1 Results in The Lancet Oncology
30 Sep 2024 18:30:00 By Nasdaq GlobeNewswire
-
Kura Oncology Appoints Michael Vasconcelles, M.D., to Board of Directors
17 Sep 2024 07:30:00 By Nasdaq GlobeNewswire
-
Kura Oncology to Participate in Cantor Global Healthcare Conference
10 Sep 2024 07:30:00 By Nasdaq GlobeNewswire
-
Kura Oncology Reports Second Quarter 2024 Financial Results
08 Aug 2024 16:05:00 By Nasdaq GlobeNewswire
-
08 Aug 2024 07:30:00 By Nasdaq GlobeNewswire
-
Kura Oncology to Report Second Quarter 2024 Financial Results
01 Aug 2024 07:30:00 By Nasdaq GlobeNewswire
-
Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
05 Jul 2024 07:30:00 By Nasdaq GlobeNewswire
-
Kura Oncology Reports Preclinical Data Supporting Potential for Menin Inhibitor in Diabetes
24 Jun 2024 07:30:00 By Nasdaq GlobeNewswire
-
Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
07 Jun 2024 07:30:00 By Nasdaq GlobeNewswire
-
Kura Oncology to Participate in Jefferies Global Healthcare Conference
29 May 2024 07:30:00 By Nasdaq GlobeNewswire
-
Kura Oncology Completes Enrollment in Registration-Directed Trial of Ziftomenib in NPM1-Mutant AML
14 May 2024 07:30:00 By Nasdaq GlobeNewswire
-
Kura Oncology to Participate in Bank of America Securities Healthcare Conference
08 May 2024 07:30:00 By Nasdaq GlobeNewswire
-
Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
03 May 2024 07:30:00 By Nasdaq GlobeNewswire
-
Kura Oncology Reports First Quarter 2024 Financial Results
02 May 2024 16:05:00 By Nasdaq GlobeNewswire
-
Kura Oncology to Report First Quarter 2024 Financial Results
25 Apr 2024 07:30:00 By Nasdaq GlobeNewswire
-
Kura Oncology Receives Breakthrough Therapy Designation for Ziftomenib in NPM1-Mutant AML
22 Apr 2024 07:30:00 By Nasdaq GlobeNewswire